SGLT2 inhibitors in older adults: overcoming the age barrier

Srikanth Bellary; Anthony H Barnett

doi:10.1016/S2666-7568(23)00039-9

SGLT2 inhibitors in older adults: overcoming the age barrier

Research output: Contribution to journal › Letter, comment/opinion or interview › peer-review

Original language	English
Pages (from-to)	e127-e128
Number of pages	2
Journal	The lancet. Healthy longevity
Volume	4
Issue number	4
DOIs	https://doi.org/10.1016/S2666-7568(23)00039-9
Publication status	Published - Apr 2023

Bibliographical note

Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. This article refers to:
Pratley, Richard E. et al (2023) Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial. The Lancet Healthy Longevity, Volume 4, Issue 4, e143 - e154. https://doi.org/10.1016/S2666-7568(23)00032-6

Keywords

Aged
Hypoglycemic Agents - therapeutic use
Humans
Diabetes Mellitus, Type 2 - drug therapy
Sodium-Glucose Transporter 2 Inhibitors - therapeutic use

Access to Document

10.1016/S2666-7568(23)00039-9Licence: CC BY-NC-ND 4.0

PIIS2666756823000399
Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license.
Final published version, 48.9 KBLicence: CC BY-NC-ND 4.0

Cite this

@article{6ca900c74abf46e9a45b7e3b97a9640e,

title = "SGLT2 inhibitors in older adults: overcoming the age barrier",

keywords = "Aged, Hypoglycemic Agents - therapeutic use, Humans, Diabetes Mellitus, Type 2 - drug therapy, Sodium-Glucose Transporter 2 Inhibitors - therapeutic use",

author = "Srikanth Bellary and Barnett, {Anthony H}",

note = "Copyright {\textcopyright} 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. This article refers to: Pratley, Richard E. et al (2023) Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial. The Lancet Healthy Longevity, Volume 4, Issue 4, e143 - e154. https://doi.org/10.1016/S2666-7568(23)00032-6 ",

year = "2023",

month = apr,

doi = "10.1016/S2666-7568(23)00039-9",

language = "English",

volume = "4",

pages = "e127--e128",

number = "4",

}

TY - JOUR

T1 - SGLT2 inhibitors in older adults: overcoming the age barrier

AU - Bellary, Srikanth

AU - Barnett, Anthony H

N1 - Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. This article refers to: Pratley, Richard E. et al (2023) Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial. The Lancet Healthy Longevity, Volume 4, Issue 4, e143 - e154. https://doi.org/10.1016/S2666-7568(23)00032-6

PY - 2023/4

Y1 - 2023/4

KW - Aged

KW - Hypoglycemic Agents - therapeutic use

KW - Humans

KW - Diabetes Mellitus, Type 2 - drug therapy

KW - Sodium-Glucose Transporter 2 Inhibitors - therapeutic use

UR - https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(23)00039-9/fulltext

UR - http://www.scopus.com/inward/record.url?scp=85151358276&partnerID=8YFLogxK

U2 - 10.1016/S2666-7568(23)00039-9

DO - 10.1016/S2666-7568(23)00039-9

M3 - Letter, comment/opinion or interview

C2 - 37003269

VL - 4

SP - e127-e128

JO - The lancet. Healthy longevity

JF - The lancet. Healthy longevity

IS - 4

ER -

SGLT2 inhibitors in older adults: overcoming the age barrier

Bibliographical note

Keywords

Access to Document

Other files and links

Cite this